Elevated Semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis.

Systemic Lupus Erythematosus

Neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus

J Rheumatol.

Moore S, Juo HH, Nielsen CT, Tyden H, Bengtsson AA, Lood C

doi: 10.3899/jrheum.190875.

Systemic Lupus Erythematosus

Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus

Rheumatology (Oxford)

Arnaud L, Mertz P, Amoura Z, Voll RE, Schwarting A, Maurier F, Blaison G, Bonnotte B, Poindron V, Fiehn C, Lorenz HM, Korganow AS, Sibilia J, Martin T

doi: 10.1093/rheumatology/keaa671

Systemic Lupus Erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

doi: 10.1136/annrheumdis-2018-214427.

Further Publications Rheumatology

Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Ann Rheum Dis

Jesus D, Larosa M, Henriques C, Matos A, Zen M, Tomé P, Alves V, Costa N, Le Guern V, Iaccarino L, Costedoat-Chalumeau N, Doria A, Inês LS

doi: 10.1136/annrheumdis-2021-220363

Systemic Lupus Erythematosus

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

J Rheumatol

Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH

doi: 10.3899/jrheum.200802

Systemic Lupus Erythematosus

Anti-tubulin-α-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations

Clin Rheumatol.

Zhao X, Cheng Y, Gan Y, Jia R, Zhu L, Sun X

doi: 10.1007/s10067-018-4024-3.

Systemic Lupus Erythematosus

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus

Ann Rheum Dis.

Reid S, Alexsson A, Frodlund M, Morris D, Sandling JK, Bolin K, Svenungsson E, Jönsen A, Bengtsson C, Gunnarsson I, Illescas Rodriguez V, Bengtsson A, Arve S, Rantapää-Dahlqvist S, Eloranta ML, Syvänen AC, Sjöwall C, Vyse TJ, Rönnblom L, Leonard D

doi: 10.1136/annrheumdis-2019-216227.

Further Publications Rheumatology

International Consensus For The Dosing Of Corticosteroids In Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis

Arthritis Rheumatol

Chalhoub NE, Wenderfer SE, Levy DM, Rouster-Stevens K, Aggarwal A, Savani SI, Ruth NM, Arkachaisri T, Qiu T, Merritt A, Onel K, Goilav B, Khubchandani RP, Deng J, Fonseca AR, Ardoin SP, Ciurtin C, Kasapcopur O, Jelusic M, Huber AM, Ozen S, Klein-Gitelman MS, Appenzeller S, Cavalcanti A, Fotis L, Sern Chin L, Silva RM, Ramírez-Miramontes J, Rosenwasser NL, Saad-Magalhaes C, Schonenberg-Meinema D, Scott C, Silva CA, Enciso S, Terreri MT, Torres-Jimenez AR, Trachana M, Al-Mayouf SM, Devarajan P, Huang B, Brunner HI, Childhood Arthritis, Rheumatology Research Alliance Lupus Nephritis Work Group, the Pediatric Rheumatology European Society Lupus Working Party.

doi: 10.1002/art.41930

Systemic Lupus Erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Arthritis Res Ther.

Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J

doi: 10.1186/s13075-019-2056-y.

Related content

Neutrophil extracellular traps identify patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus

Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

Anti-tubulin-α-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus

International Consensus For The Dosing Of Corticosteroids In Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus